Use of adenovirus and nucleic acids coding therefor
OwnerPer Sonne Holminventor
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of an adenovirus to treat cancer, for example. The adenovirus may be replication deficient in cells that lack Y box binding protein. The adenovirus may encode an oncogene or an oncogene product, which may transactivate at least one viral gene.
Claims18
-55. (canceled)
A pharmaceutical composition comprising an adenovirus, wherein the adenovirus is AdΔ24 and is replication deficient in cells that lack Y box binding protein 1 (“YB-1”) in the nucleus, and wherein the pharmaceutical composition further comprises a pharmaceutically active compound selected from the group consisting of a cytokine, a metalloproteinase inhibitor, an angiogenesis inhibitor, a cytostatic, and a cell cycle inhibitor.
A method for the treatment of cancer, comprising administering to a subject in need thereof an adenovirus, wherein the adenovirus is AdΔ24 and is replication deficient in cells that lack Y box binding protein 1 (“YB-1”) in the nucleus.
Dependencies are inferred from the claim text.